← back to ranking

COO · The Cooper Companies, Inc.

Medical - Instruments & Supplies · mkt cap $11.6B · calls: Q2 FY2026 vs Q1 FY2026
9.0 conviction · conf-adj 9

conf – 🚀 reported

triage_only:9.0

Enthusiasm latest 7 / prev 5 (rising)

AI inventory system reduces working capital; no product or revenue strategy.

PAST (realized)
CURRENT (now)
FORWARD (guidance)
TRACK RECORD — PROMISE vs DELIVERY

—/100 (no quantified promises)   no-quantified-promises  6 calls reviewed

Across six calls Cooper cites AI/ML mainly qualitatively—fertility genomics using statistical ML/AI, AI-based embryo testing, and post-reorg AI-enabled automation—without attaching numbers and deadlines to those capabilities. Quantified targets ($50M reorg savings, $2B+ FCF, MiSight ~40%, $100M MiSight) are operational, product, or cash-flow goals where AI is mentioned at most as an enabler, not as a measurable AI commitment.

PRICED-IN (REFINED)
LOW (room left)

Est. revisions flat  ·  Fwd P/E 16.3  ·  EV/Sales 3.4x

AI claim maps to Coopervision Segment, Coopersurgical Segment

Price targets fell from a ~$87 last-year average to ~$73.5 and have been flat month-over-quarter, while rating counts show only a mild shift (fewer holds, stable buy counts)—not a clear upgrade cycle baking in AI upside. Forward P/E ~16x and EV/Sales ~3.4x are moderate for med-tech, not a rich multiple that would imply transformative AI is already in the price. Modest forward revenue/EPS growth in consensus (~5–13% annually) looks like baseline ops, not an AI rerate; any efficiency or revenue lift would most plausibly flow through CooperVision and CooperSurgical, leaving room if AI benefits exceed those embedded estimates.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
5Q4 FY20242Q1 FY20252Q2 FY20252Q3 FY20252Q4 FY20252Q1 FY2026

AI enthusiasm across 6 calls — trend ↘ falling

One CooperSurgical fertility genomics ML/AI pitch in Q4 FY2024; later calls omit AI entirely.

BUSINESS IMPACT - QUALITATIVE MATERIALITY

4/10 qualitative impact   moderate  near-term · mixed evidence

Where AI matters: back-office OpEx, shared services, margin

Cooper credibly deploys AI for internal automation in marketing, planning, forecasting, and support alongside a smaller org, with flat OpEx and cited margin help, but management never isolates AI dollars or KPIs and bundles gains with reorg and prior IT—no AI in core product revenue.

Caveats: AI ROI unquantified and inseparable from reorg synergies; Prior fertility genomics ML pitch dropped from recent calls—no durable product AI narrative; Back-office efficiency is replicable by peers without topline differentiation; CEO enthusiasm may outrun attributable margin lift

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 2/10

The model sells regulated contact lenses and surgical/fertility devices and consumables with clinical, manufacturing, and channel moats; AI does not commoditize or automate away the physical products or the compliance-heavy sale, and billable-hour or content deflation risks do not apply.

OPTIONS / MARKET STRUCTURE

option liquidity: fair

ATM IV
—
TYPICAL BID-ASK
—
OPEN INTEREST
—

proxy inputs — dollar-ADV $134M · beta 0.894 · px $59.49

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders buying, institutions adding, management language 1/10 hedged.
INSIDERS buying 5 open-market buy(s) vs 0 sell(s) — net accumulation
INSTITUTIONS (13F) adding as of 2026-03-31: 102 new / 104 closed positions; 339 increased / 238 reduced; institutional ownership +1.62pp; -1 net 13F holders
MGMT LANGUAGE 1/10 hedged No AI/ML discussed; one automation product cite, otherwise generic tech efficiency.
commit “Witness, our automated lab tracking system”
hedge “continuing to build a streamlined and technologically efficient company”
VERBATIM AI QUOTES
“These efficiencies stem from the structural changes we've made as we transition to a smaller, more efficient organization that leverages technology including AI to automate work and optimize shared services.”
— Brian Andrews, Q1 FY2026
“we're increasingly applying AI-enabled tools to streamline areas such as marketing, planning, forecasting and support functions.”
— Brian Andrews, Q1 FY2026
“I would kind of highlight AI, and I hate to sound like one more person talking about it. But the reality is that our organization has embraced it. And this isn't our organization like all of a sudden right now getting on and training and everyone's going to train on it and so forth. Our organization embraced it last summer. And we started implementing that stuff as we were going through the year, and we're seeing positives come out of that type of work. The technology advancements at Cooper are fantastic. I'm super happy. And we have a lot more to do. This isn't a 1-quarter thing. So we saw some of it certainly in Q4. We're seeing those improvements in Q1, and we're going to continue to see the use of technology and AI advancements be a positive to us on our operating margins as we move through this year.”
— Albert White, Q1 FY2026
“here again in Q1, OpEx was roughly flat year-over-year. So there's a lot that we're doing to drive synergies and efficiencies, leveraging prior investment activity, and we're just really being very disciplined about fixed costs in the back office. And so we want to leverage IT. We're doing that much, much more than ever before, as Al talked about.”
— Brian Andrews, Q1 FY2026
“By leveraging prior IT investments, supported by AI capabilities, We integrated key support functions and are unlocking meaningful productivity gains.”
— Brian Andrews, Q4 FY2025
“tighter working capital management supported by a streamlined and AI-enabled operating structure.”
— Brian Andrews, Q4 FY2025
“And, frankly, you hear people talk about AI all the time. Well, it is real. And, you”
— Albert White, Q4 FY2025